Patents Assigned to Insect Biotech Co., Ltd.
-
Patent number: 8367060Abstract: The present invention relates to a composition and a method for the treatment of liver dysfunction which contains administration of a composition containing arazyme as an active ingredient, more precisely arazyme produced by Aranicola proteolyticus. The arazyme of the present invention inhibits apoptosis in injured liver cells, increases SMP30 expression, inhibits P-smad3 expression and protects the liver by inhibiting liver injury around the central vein region. Therefore, the arazyme of the invention can be effectively used as a composition for the treatment of liver dysfunction.Type: GrantFiled: September 16, 2011Date of Patent: February 5, 2013Assignee: Insect Biotech Co., Ltd.Inventors: Ho-Yong Park, Kwang-Hee Son, Dong-Ha Shin, Kyu-Shik Jeong
-
Publication number: 20120003205Abstract: The present invention relates to a pharmaceutical composition for the prevention of liver dysfunction which contains arazyme as an active ingredient, more precisely a pharmaceutical composition for treating liver dysfunction which contains arazyme produced by Aranicola proteolyticus. The arazyme of the present invention inhibits apoptosis in injured liver cells, increases SMP30 expression, inhibits P-smad3 expression and protects liver by inhibiting liver injury around central vein region. Therefore, the arazyme of the invention can be effectively used as a pharmaceutical composition for the prevention of liver dysfunction.Type: ApplicationFiled: September 16, 2011Publication date: January 5, 2012Applicant: INSECT BIOTECH CO., LTD.Inventors: Ho-Yong PARK, Kwang-Hee SON, Dong-Ha SHIN, Kyu-Shik JEONG
-
Publication number: 20120003204Abstract: The present invention relates to a pharmaceutical composition for the prevention and treatment of cancer comprising arazyme as an active ingredient. More precisely, when arazyme produced by Aranicola proteolycius was administered to the nude mice transplanted with human lung carcinoma cell line, weight gaining, inhibition of tumor cell growth and infiltration, and down-regulations of MMP-9, NF-?B and PCNA, were observed. In addition, when arazyme was treated to human breast cancer cells (MDA-MB-231), down regulations of p21, PCNA (Proliferating Cell Nuclear Antigen), VEGF (Vascular Endothelial Growth Factor), BCl2 (B-cell CLL/lymphoma 2), p-p38, PKC (Protein Kinase C) and MMP-1 (Matrix MetalloProteinase-1) which are involved in tumor cell growth, differentiation, proliferation and metastasis, were observed along with the up-regulation of catalase which inhibits tumor development. Therefore, the arazyme can be effectively used as a pharmaceutical composition for the prevention and treatment of cancer.Type: ApplicationFiled: September 2, 2011Publication date: January 5, 2012Applicant: INSECT BIOTECH CO., LTD.Inventors: Ho-Yong PARK, Kwang-Hee SON, Dong-Ha SHIN, Kyu-Shik JEONG
-
Publication number: 20100322917Abstract: The present invention relates to a pharmaceutical composition for the prevention of liver dysfunction which contains arazyme as an active ingredient, more precisely a pharmaceutical composition for the prevention of liver dysfunction which contains arazyme produced by Aranicola proteolyticus. The arazyme of the present invention inhibits apoptosis in injured liver cells, increases SMP30 expression, inhibits P-smad3 expression and protects liver by inhibiting liver injury around central vein region. Therefore, the arazyme of the invention can be effectively used as a pharmaceutical composition for the prevention of liver dysfunction.Type: ApplicationFiled: December 28, 2006Publication date: December 23, 2010Applicant: INSECT BIOTECH CO., LTD.Inventors: Ho-Yong Park, Kwang-Hee Son, Dong-Ha Shin, Kyu-Shik Jeong
-
Publication number: 20100278806Abstract: Disclosed herein is a composition containing arazyme as an active ingredient for prevention and treatment of arthritis. More specifically, arazyme produced from Aranicola proteolyticus of the present invention may be useful as a composition for prevention and treatment of arthritis by inhibiting the expression of TNF-? which is an inflammation-inducing factor and preventing the loss of proteoglycan and collagen from joint cartilage to inhibit the progression of arthritis and protect joints.Type: ApplicationFiled: January 9, 2009Publication date: November 4, 2010Applicant: Insect Biotech Co., Ltd.Inventors: Ho-Yong Park, Kwang-Hee Son, Dong-Ha Shin, Kyu-Shik Jeong
-
Publication number: 20090317374Abstract: The present invention relates to a pharmaceutical composition for the prevention and treatment of cancer comprising arazyme as an active ingredient. More precisely, when arazyme produced by Aranicola proteolycius was administered to the nude mice transplanted with human lung carcinoma cell line, weight gaining, inhibition of tumor cell growth and infiltration, and down-regulations of MMP-9, NF-?B and PCNA, were observed. In addition, when arazyme was treated to human breast cancer cells (MDA-MB-231), down regulations of p21, PCNA (Proliferating Cell Nuclear Antigen), VEGF (Vascular Endothelial Growth Factor), BCl2 (B-cell CLL/lymphoma 2), p-p38, PKC (Protein Kinase C) and MMP-1 (Matrix MetalloProteinase-1) which are involved in tumor cell growth, differentiation, proliferation and metastasis, were observed along with the up-regulation of catalase which inhibits tumor development. Therefore, the arazyme can be effectively used as a pharmaceutical composition for the prevention and treatment of cancer.Type: ApplicationFiled: December 28, 2007Publication date: December 24, 2009Applicant: INSECT BIOTECH CO., LTD.Inventors: Ho-Yong Park, Kwang-Hee Son, Dong-Ha Shin, Kyu-Shik Jeong
-
Patent number: 7083968Abstract: The present invention relates to a novel microbe belonging to Serratia family, its isolation method and the preparation method using it. More particularly, the present invention relates to a microorganism of Serratia family producing laccase, lignin peroxidase and Mn-dependent-peroxidase which are the kinds of lignin lyases, and a method for separating the microbe from insect gut, as well as a method for preparing laccase, lignin peroxidase and Mn-dependent-peroxidase. The microorganism of the present invention can be used not only in the treatment of industrial sewage and harmful environmental substance but also in oil degradation, in biological bleaching of pulp since it can produce lignin lyases. More over, the microbe can also be used effectively in industry of preparing fuel, forage and other chemicals through lignin degradation.Type: GrantFiled: July 31, 2001Date of Patent: August 1, 2006Assignee: Insect Biotech Co., Ltd.Inventors: Ho Yong Park, Ki Duk Kim, Dong Ha Shin